145 related articles for article (PubMed ID: 30105759)
1. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.
Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D
J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma.
Liu C; Li Y; Wei M; Zhao L; Yu Y; Li G
Cell Cycle; 2019 Mar; 18(5):568-579. PubMed ID: 30727821
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
4. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model.
Sun N; Chu J; Hu W; Chen X; Yi N; Shen Y
Sci Rep; 2022 Jan; 12(1):27. PubMed ID: 34996932
[TBL] [Abstract][Full Text] [Related]
5. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
6. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
7. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
8. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
9. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y
Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
11. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
12. High Expression of Krüppel-like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients with Lung Adenocarcinoma.
Niu R; Tang Y; Xi Y; Jiang D
J Surg Res; 2020 Jun; 250():216-223. PubMed ID: 32092599
[TBL] [Abstract][Full Text] [Related]
13. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.
Zhang L; Zhang Z; Yu Z
J Transl Med; 2019 Dec; 17(1):423. PubMed ID: 31847905
[TBL] [Abstract][Full Text] [Related]
15. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
16. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis.
Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ
Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191
[No Abstract] [Full Text] [Related]
17. Reverse engineering a predictive signature characterized by proliferation, DNA damage, and immune escape from stage I lung adenocarcinoma recurrence.
Yao J; Xue X; Qu D; Westphalen CB; Ge Y; Zhang L; Li M; Gao T; Chandrakesan P; Vega KJ; Peng J; An G; Weygant N
Acta Biochim Biophys Sin (Shanghai); 2020 Jun; 52(6):638-653. PubMed ID: 32395755
[TBL] [Abstract][Full Text] [Related]
18. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
19. Exploring the survival prognosis of lung adenocarcinoma based on the cancer genome atlas database using artificial neural network.
Jiang N; Xu X
Medicine (Baltimore); 2019 May; 98(20):e15642. PubMed ID: 31096483
[TBL] [Abstract][Full Text] [Related]
20. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.
Liu WT; Wang Y; Zhang J; Ye F; Huang XH; Li B; He QY
Cancer Lett; 2018 Jul; 425():43-53. PubMed ID: 29608985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
